Aims: Dengue virus is a global pathogen that lacks an effective vaccine or therapy. Screening medicinal plants for anti-dengue properties provides a promising avenue to identify potent compounds. Mangroves, known for their resilience in harsh conditions, produce a diverse range of natural products with unique biochemical profiles, which hold potential for anti-dengue treatments. This study aims to evaluate the anti-dengue activity of selected mangrove plant species from Sabah against DENV2 NS2B-NS3pro, utilizing an enzymatic protease assay. Methodology and results : Six mangrove species (Avicennia marina, Bruguiera gymnorrhiza, Ceriops tagal, Rhizophora apiculata, Rhizophora mucronata and Xylocarpus granatum) were investigated, with various plant parts subjected to aqueous and ethanol extraction. The results demonstrated significant anti-dengue activity in both aqueous and ethanolic extracts of the mangroves against DENV2 NS2B-NS3pro, with IC50 values ranging from 0.95 µg/mL to 6.24 µg/mL. Notably, the ethanolic extract of R. apiculata leaves exhibited the highest inhibition, with an IC50 value of 0.95 µg/mL. Conclusion, significance and impact of study These findings suggest that the ethanolic extracts from R. apiculata leaves hold promise as potential candidates for dengue treatment. This study underscores the importance of natural products as valuable sources for the development of novel anti-dengue treatments, highlighting the need to explore mangroves in the quest for effective therapeutic options.

Mycobacterium tuberculosis (MTB) is a highly adaptive pathogen that emerged as a devastating and mortality-related disease agent. The limited efficacy of the Mycobacterium bovis BCG vaccine, antibiotics and intensive treatment to prevent mortality have piqued researchers' interest in host-pathogen interactions. Besides the emergence of multi-drug resistant TB as a drawback, the host immune responses could be successfully subverted and exploited by the MTB-host pathogenesis during the early stages of innate immunity. Factors contributing to mycobacterial pathogenesis are concomitant and multifactorial, including virulence factors such as adhesins, toxins and enzymes that drive the progression of MTB infection. Initially, alveolar macrophage (AM), which has been considered to restrain bacterial growth, facilitates the spread of disease through interactions with MTB. The progression to bacterial replication and systemic infection before the initiation of cell-mediated immunity (CMI) indicates a delay in the activation of adaptive immunity, which is crucial. The findings are supported by the bacterial multiplication and dissemination in the infected alveolar macrophage in animal models. On the other hand, mangrove plants have revealed a structural diversity and a plethora of compounds responsible for antibacterial, antifungal and antiviral activities. These may serve as potential bioactive compounds for anti-TB drugs. In this review, we discuss mycobacterial colonisation, tissue invasion and host inflammatory responses that lead to the pathogenesis of MTB, along with the potential bioactive compounds for alternative plant-derived anti-TB drugs. The mechanistic insights provide significant discoveries on the limitations of immunity, offering important strategies for developing immunomodulating drugs.